RUNX2 is a member of the RUNX family of transcription factors, also containing the RUNX1 and RUNX3 proteins. These factors control the expression of genes essential for proper development in many cell lineages. RUNX2 plays a crucial role in the proliferation and differentiation of osteoblasts, required for bone formation. The cellular level of RUNX2 oscillates in a cell phase-specific manner, reaching a maximum at G2/M in some cells and overexpression of RUNX2 in osteoblasts blocked G1 to S phase progression. Recent studies have shown that RUNX2 may interact with p53 and change the activity of a histone deacetylase. Moreover, RUNX2 may act as an oncogene in cancer transformation, inevitably associated with genomic instability evoked by increased occurrence of DNA damage. We showed that some RUNX2 modifiers changed the sensitivity of differentiating preosteoblasts to DNA damage induced by oxidative stress. All these data suggest the involvement of RUNX2 in cellular DNA damage response (DDR), which is particularly important in osteogenesis as the process of osteoblast differentiation is associated with increasing oxidative stress. However, the mechanism underlying DDR involvement of RUNX2 is unknown. The basic question, whether RUNX2 plays a positive or destructive role in DDR in differentiating cells is still open.
Get full access to this article
View all access options for this article.
References
1.
ApplefordP.J., and WoollardA. (2009). RUNX genes find a niche in stem cell biology. J Cell Biochem, 108, 14–21.
2.
ArakakiN., YamashitaA., NiimiS., and YamazakiT. (2013). Involvement of reactive oxygen species in osteoblastic differentiation of MC3T3-E1 cells accompanied by mitochondrial morphological dynamics. Biomed Res, 34, 161–166.
3.
BaeS.C., and LeeY.H. (2006). Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gen, 366, 58–66.
4.
BenesF.M., LimB., MatzilevichD., WalshJ.P., SubbarajuS., and MinnsM. (2007). Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A, 104, 10164–10169.
5.
Bernardin-FriedF., KummalueT., LeijenS., CollectorM.I., RavidK., and FriedmanA.D. (2004). AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem, 279, 15678–15687.
6.
BlythK., CameronE.R., and NeilJ.C. (2005). The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer, 5, 376–387.
7.
BlythK., TerryA., MackayN., VaillantF., BellM., CameronE.R., NeilJ.C., and StewartM. (2001). Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene, 20, 295–302.
8.
BlythK., VaillantF., HanlonL., MackayN., BellM., JenkinsA., NeilJ.C., and CameronE.R. (2006). Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res, 66, 2195–2201.
9.
BlythK., VaillantF., JenkinsA., McDonaldL., PringleM.A., HuserC., SteinT., NeilJ., and CameronE.R. (2010). Runx2 in normal tissues and cancer cells: a developing story. Blood Cells Mol Dis, 45, 117–123.
10.
BraunT., and WoollardA. (2009). RUNX factors in development: lessons from invertebrate model systems. Blood Cells Mol Dis, 43, 43–48.
11.
BurkhartD.L., and SageJ. (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer, 8, 671–682.
12.
CaloE., Quintero-EstadesJ.A., DanielianP.S., NedelcuS., BermanS.D., and LeesJ.A. (2010). Rb regulates fate choice and lineage commitment in vivo. Nature, 466, 1110–1114.
13.
CameronE.R., and NeilJ.C. (2004). The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene, 23, 4308–4314.
14.
CamilleriS., and McDonaldF. (2006). Runx2 and dental development. Eur J Oral Sci, 114, 361–373.
15.
ChenA.I., de NooijJ.C., and JessellT.M. (2006). Graded activity of transcription factor Runx3 specifies the laminar termination pattern of sensory axons in the developing spine. Neuron, 49, 395–408.
16.
ChuangL.S., ItoK., and ItoY. (2013). RUNX family: regulation and diversification of roles through interacting proteins. Int J Cancer, 132, 1260–1271.
17.
CohenM.M.Jr. (2006). The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet Part A, 140A, 2646–2706.
18.
CohenM.M.Jr. (2009). Perspectives on RUNX genes: an update. Am J Med Genet A, 149A, 2629–2646.
19.
CorneyD.C., Flesken-NikitinA., GodwinA.K., WangW., and NikitinA.Y. (2007). MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res, 67, 8433–8438.
20.
DongY.F., Soung DoY., SchwarzE.M., O'KeefeR.J., and DrissiH. (2006). Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol, 208, 77–86.
21.
DurstK.L., and HiebertS.W. (2004). Role of RUNX family members in transcriptional repression and gene silencing. Oncogene, 23, 4220–4224.
22.
EngelmanJ.A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 9, 550–562.
23.
FierroF., IllmerT., JingD., SchleyerE., EhningerG., BoxbergerS., and BornhauserM. (2007). Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif, 40, 355–366.
24.
FujitaT., AzumaY., FukuyamaR., HattoriY., YoshidaC., KoidaM., OgitaK., and KomoriT. (2004). Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol, 166, 85–95.
25.
FuldaS. (2013). Modulation of mitochondrial apoptosis by PI3K inhibitors. Mitochondrion, 13, 195–198.
26.
GalindoM., PratapJ., YoungD.W., HovhannisyanH., ImH.J., ChoiJ.Y., LianJ.B., SteinJ.L., SteinG.S., and van WijnenA.J. (2005). The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem, 280, 20274–20285.
27.
GaurT., LengnerC.J., HovhannisyanH., BhatR.A., BodineP.V., KommB.S., JavedA., van WijnenA.J., SteinJ.L., SteinG.S., and LianJ.B. (2005). Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem, 280, 33132–33140.
28.
GergenJ.P., and ButlerB.A. (1988). Isolation of the Drosophila segmentation gene runt and analysis of its expression during embryogenesis. Genes Dev, 2, 1179–1193.
29.
GionoL.E., and ManfrediJ.J. (2006). The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol, 209, 13–20.
30.
HechtJ., StrickerS., WiechaU., StiegeA., PanopoulouG., PodsiadlowskiL., PoustkaA.J., DieterichC., EhrichS., SuvorovaJ., MundlosS., and SeitzV. (2008). Evolution of a core gene network for skeletogenesis in Chordates. PLos Genet, 4, e1000025.
31.
HeidariN., MillerA.V., HicksM.A., MarkingC.B., and HaradaH. (2012). Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells. Cell Death Dis, 3, e349.
32.
HemmingsB.A., and RestucciaD.F. (2012). PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol, 4, a011189.
33.
InoueK., ShigaT., and ItoY. (2008). Runx transcription factors in neuronal development. Neural Dev, 26, 3–20.
34.
ItoY. (2004). Oncogenic potential of the RUNX gene family: ‘overview’. Oncogene, 23, 4198–4208.
JönssonS., Hjorth-HansenH., OlssonB., WadenvikH., SundanA., and StandalT. (2012). Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab, 30, 119–123.
40.
JuricD., LacayoN.J., RamseyM.C., RacevskisJ., WiernikP.H., RoweJ.M., GoldstoneA.H., O'DwyerP.J., PaiettaE., and SikicB.I. (2007). Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol, 25, 1341–1349.
41.
JuvenT., BarakY., ZaubermanA., GeorgeD.L., and OrenM. (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene, 8, 3411–3416.
42.
KaminkerJ.S., SinghR., LebestkyT., YanH., and BanerjeeU. (2001). Redundant function of Runt domain binding partners, Big brother and Brother, during Drosophila development. Development, 128, 2639–2648.
43.
KazantsevA., and SancarA. (1995). Does the p53 up-regulated Gadd45 protein have a role in excision repair?. Science, 270, 1003–1006.
44.
KimH.J., KimJ.H., BaeS.C., ChoiJ.Y., KimH.J., and RyooH.M. (2003). The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem, 278, 319–326.
45.
KomoriT. (2002). Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem, 87, 1–8.
46.
KomoriT. (2005). Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem, 95, 445–453.
47.
KomoriT. (2010). Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res, 339, 189–195.
48.
LevanonD., and GronerY. (2004). Structure and regulated expression of mammalian RUNX genes. Oncogene, 23, 4211–4219.
49.
LengnerC.J., SteinmanH.A., GagnonJ., SmithT.W., HendersonJ.E., KreamB.E., SteinG.S., LianJ.B., and JonesS.N. (2006). Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol, 172, 909–921.
50.
LianJ.B., SteinJ.L., SteinG.S., van WijnenA.J., MontecinoM., JavedA., GutierrezS., ShenJ., ZaidiS.K., and DrissiH. (2003). Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res, 44Suppl 1, 141–148.
51.
LiuH., and LiB. (2010). p53 control of bone remodeling. J Cell Biochem, 111, 529–534.
52.
LouZ., Minter-DykhouseK., WuX., and ChenJ. (2003). MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature, 421, 957–961.
53.
LutterbachB., WestendorfJ.J., LinggiB., IsaacS., SetoE., and HiebertS.W. (2000). A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem, 275, 651–656.
54.
McCarthyT.L., ChangW.Z., LiuY., and CentrellaM. (2003). Runx2 integrates estrogen activity in osteoblasts. J Biol Chem, 278, 43121–43129.
55.
McGee-LawrenceM.E., BradleyE.W., DudakovicA., CarlsonS.W., RyanZ.C., KumarR., DadsetanM., YaszemskiM.J., ChenQ., AnK.N., and WestendorfJ.J. (2013). Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone, 52, 296–307.
56.
MundlosS. (1999). Cleidocranial dysplasia: clinical and molecular genetics. J Med Genet, 36, 177–182.
57.
NeilJ., CameronE., StewartM., BlythK., VaillantF., MingH., TerryA., MackayN., and BellB. (2000). In vivo and in vitro analysis of Cbfa1/Runx2 oncogenic functions. International Workshop on Runt-Domain Transcription Factors, Kyoto, Japan, July 17–20.
58.
NicolaijeC., KoedamM., and van LeeuwenJ.P. (2012). Decreased oxygen tension lowers reactive oxygen species and apoptosis and inhibits osteoblast matrix mineralization through changes in early osteoblast differentiation. J Cell Physiol, 227, 1309–1318.
59.
NimmoR., and WoollardA. (2008). Worming out the biology of Runx. Dev Biol, 313, 492–500.
60.
OttoF., LübbertM., and StockM. (2003). Upstream and downstream targets of RUNX proteins. J Cell Biochem, 89, 9–18.
61.
OzakiT., NakagawaraA., and NagaseH. (2013a). Family participates in the regulation of p53-dependent DNA damage response. Int J Genomics, 2013, 271347.
62.
OzakiT., WuD., SugimotoH., NagaseH., and NakagawaraA. (2013b). Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis, 4, e610.
63.
QiaoM., ShapiroP., FosbrinkM., RusH., KumarR., and PassanitiA. (2006). Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem, 281, 7118–7128.
64.
QiaoM., ShapiroP., KumarR., and PassanitiA. (2004). Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem, 279, 42709–42718.
65.
QinL., RaggattL.J., and PartridgeN.C. (2004). Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab, 15, 60–65.
66.
PandeS., BrowneG., PadmanabhanS., ZaidiS.K., LianJ.B., van WijnenA.J., SteinJ.L., and SteinG.S. (2013). Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol, 228, 1784–1792.
67.
PaullT.T., RogakouE.P., YamazakiV., KirchgessnerC.U., GellertM., and BonnerW.M. (2000). A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol, 10, 886–895.
68.
PawlowskaE., WysokińskiD., TokarzP., Piastowska-CiesielskaA., SzczepanskaJ., and BlasiakJ. (2014). Role of RUNX2 modifiers, dexamethasone and 1,25-dihydroxyvitamin D3, in the cellular response to DNA damage induced by oxidative stress in osteoblasts differentiation. Int J Mol Sci, 15, 16649–16664.
69.
PelletierN., ChampagneN., StifaniS., and YangX.J. (2002). MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene, 21, 2729–2740.
70.
PengX.D., XuP.Z., ChenM.L., Hahn-WindgassenA., SkeenJ., JacobsJ., SundararajanD., ChenW.S., CrawfordS.E., ColemanK.G., and HayN. (2003). Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev, 17, 1352–1365.
71.
RajgopalA., YoungD.W., MujeebK.A., SteinJ.L., LianJ.B., van WijnenA.J., and SteinG.S. (2007). Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J Cell Biochem, 100, 1509–1517.
72.
RoosW.P., and KainaB. (2006). DNA damage-induced cell death by apoptosis. Trends Mol Med, 12, 440–450.
73.
SchäferA. (2013). Gadd45proteins: key players of repair-mediated DNA demethylation. Adv Exp Med Biol, 793, 35–50.
74.
SchnerchD., LauschE., BeckerH., FelthausJ., PfeiferD., MundlosS., EngelhardtM., SchwabeM., and WäschR. (2014). Up-regulation of RUNX2 in acute myeloid leukemia in a patient with an inherent RUNX2 haploinsufficiency and cleidocranial dysplasia. Leuk Lymphoma, 55, 1930–1932.
75.
SchroederT.M., JensenE.D., and WestendorfJ.J. (2005). Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today, 75, 213–225.
76.
SchroederT.M., KahlerR.A., LiX., and WestendorfJ.J. (2004). Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem, 279, 41998–42007.
77.
SchwartzD., and RotterV. (1998). p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol, 8, 325–336.
78.
ShaulianE., ZaubermanA., MilnerJ., DaviesE.A., and OrenM. (1993). Tight DNAbinding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J, 12, 2789–2797.
79.
SionovR.V., and HauptY. (1999). The cellular response to p53: the decision between life and death. Oncogene, 18, 6145–6157.
80.
SteinG.S., LianJ.B., van WijnenA.J., SteinJ.L., MontecinoM., JavadA., ZaidiS.K., YoungD.W., ChoiJ.-Y., and PockwinseS.M. (2004). Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene, 23, 4315–4329.
81.
StewartM., MacKayN., CameronE.R., and NeilJ.C. (2002). The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. J Virol, 76, 4364–4369.
82.
SubramanianC., JarzembowskiJ.A., OpipariA.W.Jr., CastleV.P., and KwokR.P. (2011). HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia, 13, 726–734.
83.
SunL., VitoloM.I., QiaoM., AnglinI.E., and PassanitiA. (2004). Regulation of TGFbeta1-mediated growth inhibition and apoptosis by RUNX2 isoforms in endothelial cells. Oncogene, 23, 4722–4734.
84.
TakaradaT., and YonedaY. (2009). Transactivation by Runt-related factor-2 of matrix metalloproteinase-13 in astrocytes. Neurosci Lett, 451, 99–104.
85.
TanakaH., ArakawaH., YamaguchiT., ShiraishiK., FukudaS., MatsuiK., TakeiY., and NakamuraY. (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature, 404, 42–49.
86.
TandonM., ChenZ., and PratapJ. (2014). Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells. J Cell Biochem, 115, 2208–2217.
87.
TerryA., KilbeyA., VaillantF., StewartM., JenkinsA., CameronE., and NeilJ.C. (2004). Conservation and expression of an alternative 31 exon of Runx2 encoding a novel proline-rich C-terminal domain. Gene, 336, 115–125.
88.
ThomasD.M., CartyS.A., PiscopoD.M., LeeJ.S., WangW.F., ForresterW.C., and HindsP.W. (2001). The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell, 8, 303–316.
89.
ThomasD.M., JohnsonS.A., SimsN.A., TrivettM.K., SlavinJ.L., RubinB.P., WaringP., McArthurG.A., WalkleyC.R., HollowayA.J., DiyagamaD., GrimJ.E., ClurmanB.E., BowtellD.D., LeeJ.S., GutierrezG.M., PiscopoD.M., CartyS.A., and HindsP.W. (2004). Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol, 167, 925–934.
90.
TibulloD., GiallongoC., LaC.P., BerrettaS., StagnoF., ChiarenzaA., ConticelloC., PalumboG.A., and DiR.F. (2009). Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol, 37, 461–468.
91.
TintutY., ParharniF., LiV., KarsentyG., and DemerL.L. (1999). Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem, 274, 28875–28879.
92.
VaillantF., BlythK., TerryA., BellM., CameronE.R., NeilJ., and StewartM. (1999). A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene, 18, 7124–7134.
93.
van der DeenM., TaipaleenmäkiH., ZhangY., TeplyukN.M., GuptaA., CinghuS., ShogrenK., MaranA., YaszemskiM.J., LingL., CoolS.M., LeongD.T., DierkesC., ZustinJ., Salto-TellezM., ItoY., BaeS.C., ZielenskaM., SquireJ.A., LianJ.B., SteinJ.L., ZambettiG.P., JonesS.N., GalindoM., HesseE., SteinG.S., and van WijnenA.J. (2013). MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem, 288, 21307–21319.
VessoniA.T., Filippi-ChielaE.C., MenckC.F., and LenzG. (2013). Autophagy and genomic integrity. Cell Death Differ, 20, 1444–1454.
96.
VillagraA., CruzatF., CarvalloL., ParedesR., OlateJ., van WijnenA.J., SteinG.S., LianJ.B., SteinJ.L., ImbalzanoA.N., and MontecinoM. (2006). Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein b-dependent recruitment of SWI/SNF activity. J Biol Chem, 281, 22695–22706.
97.
VladimirovaV., WahaA., LuckerathK., PeshevaP., and ProbmeisterR. (2008). Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J Neurosci Res, 86, 2450–2461.
98.
WangC.Q., JacobB., NahG.S., and OsatoM. (2010). Runx family genes, niche, and stem cell quiescence. Blood Cells Mol Dis, 44, 275–278.
99.
WangL., HuangG., ZhaoX., HatlenM.A., VuL., LiuF., and NimerS.D. (2009). Posttranslational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis, 43, 30–34.
100.
WangS., WangQ., CruteB.E., MelnikovaI.N., KellerS.R., and SpeckN.A. (1993). Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol, 13, 3324–3339.
101.
WangW., WangY.G., ReginatoA.M., GlotzerD.J., FukaiN., PlotkinaS., KarsentyG., and OlsenB.R. (2004). Groucho homologue Grg5 interacts with the transcription factor Runx2-Cbfa1 and modulates its activity during postnatal growth in mice. Dev Biol, 270, 364–381.
WestendorfJ.J., ZaidiS.K., CascinoJ.E., KahlerR., van WijnenA.J., LianJ.B., YoshidaM., SteinG.S., and LiX. (2002). Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol, 22, 7982–7992.
104.
WoolfE., XiaoC., FainaruO., LotemJ., RosenD., NegreanuV., BernsteinY., GoldenbergD., BrennerO., BerkeG., LevanonD., and GronerY. (2003). Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci U S A, 100, 7731–7736.
105.
XiaoG., JiangD., ThomasP., BensonM.D., GuanK., KarsentyG., and FranceschiR.T. (2000). MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem, 275, 4453–4459.
106.
XiaoG., WangD., BensonM.D., KarsentyG., and FranceschiR.T. (1998). Role of the alpha2-integrin in osteoblast- specific gene expression and activation of the Osf2 transcription factor. J Biol Chem, 273, 32988–32994.
107.
YoshidaC.A., YamamotoH., FujitaT., FuruichiT., ItoK., InoueK.-I., YamanaK., ZanmaA., TakadaK., ItoY., and KomoriT. (2004). Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev, 18, 952–963.
108.
YoungD.W., HassanM.Q., PratapJ., GalindoM., ZaidiS.K., LeeS.H., YangX., XieR., JavedA., UnderwoodJ.M., FurcinittiP., ImbalzanoA.N., PenmanS., NickersonJ.A., MontecinoM.A., LianJ.B., SteinJ.L., van WijnenA.J., and SteinG.S. (2007). Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature, 445, 442–446.
109.
ZagamiC.J., ZussoM., and StifaniS. (2009). Runx transcription factors: lineage-specific regulators of neuronal precursor cell proliferation and post-mitotic neuron subtype development. J Cell Biochem, 107, 1063–1072.
110.
ZambottiA., MakhlufH., ShenJ., and DucyP. (2002). Characterization of an osteoblast-specific enhancer element in the CBFA1 gene. J Biol Chem, 277, 41497–41506.
111.
ZhangR.P., ShaoJ.Z., and XiangL.X. (2011). GADD45A protein plays an essential role in active DNA demethylation during terminal osteogenic differentiation of adipose-derived mesenchymal stem cells. J Biol Chem, 286, 41083–41094.
112.
ZirosP.G., GeorgakopoulosT., HabeosI., BasdraE.K., and PapavassiliouA.G. (2004). Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat3. J Bone Miner Res, 19, 1892–1904.
